Facial allotransplantation restores normal anatomy to severely disfigured faces. Although >30 such operations performed worldwide have yielded promising short-term results, data on long-term outcomes remain scarce. Three full-face transplant recipients were followed for 40 months. Severe changes in volume and composition of the facial allografts were noted. Data from computed tomography performed 6, 18 and 36 months after transplantation were processed to separate allograft from recipient tissues and further into bone, fat and nonfat soft tissues. Skin and muscle biopsies underwent diagnostic evaluation. All three facial allografts sustained significant volume loss (mean 19.55%) between 6 and 36 months after transplant. Bone and nonfat soft tissue volumes decreased significantly over time (17. 22% between months 6 and 18 and 25.56% between months 6 and 36, respectively), whereas fat did not. Histological evaluations showed atrophy of muscle fibers. Volumetric and morphometric changes in facial allografts have not been reported previously. The transformation of facial allografts in this study resembled aging through volume loss but differed substantially from regular aging. These findings have implications for risk-benefit assessment, donor selection and measures counteracting muscle and bone atrophy. Superior long-term outcomes of facial allotransplantation will be crucial to advance toward future clinical routine.
Introduction
Facial allotransplantation is a one-step procedure that aims to restore severely disfigured faces (1, 2) . Promising shortterm results have driven this approach forward, with >30 face transplantations performed to date (3) . In this context, facial allografts were recently added to the definition of organs covered by the National Organ Transplant Act (4); however, long-term outcome reports must become available to further evaluate this intervention (5) . We noted clinical and volumetric changes in facial allografts over 36 months of careful follow-up of three full-face transplant recipients at our institution ( Figure 1 , Table 1 ). These changes affect long-term outcomes, may affect surgical planning and donor selection in future interventions, and must be considered within the context of remedial measures. We report our investigation of these morphologic and volumetric changes in three full-face transplants and suggest novel secondary treatment options that potentially improve long-term outcomes.
Materials and Methods
All patients provided written informed consent to participate in the clinical trial for face transplantation (ClinicalTrials.gov, NCT01281267), as approved by the Partners Human Research Committee at Brigham and Women's Hospital and by the Army Medical Research and Materiel Command Human Research Protection Office.
All patients received full facial allotransplantation in 2011. Photographs of the patients' faces were taken, and patient weight was assessed at 6, 18, and 36 months of follow-up.
Computed tomography acquisition and image reconstruction
Dedicated computed tomography (CT) examinations were performed at 6, 18 and 36 months after transplantation using a first-generation 320 Â 0.5-mm detector row scanner (Aquilion One; Toshiba Medical Systems, Tochigi-ken, Japan). Imaging details have been reported (6) (7) (8) . For this project, 1 Â 0.5-mm (overlapping) reconstructed images were transferred to a dedicated workstation (Vitrea version 6.1; Vital Images, Minnetonka, MN). A radiologist separated allograft and recipient tissues by direct planimetry on a slice-by-slice basis; all tissue boundaries were confirmed by the plastic surgeon leading the transplant team and corrected, Figure 1 : Photographs of the three patients at 6, 18, and 36 months after transplantation. Shown is the appearance 6 months (left column), 18 months (middle column), and 36 months (right column) after transplantation. All patients provided written consent for publication of their photographs. if necessary. The three allograft tissue types (bone and fat and nonfat soft tissue) were segmented using CT density semiautomated methods that were confirmed and corrected, as needed, by the radiologist. Union of donor and recipient bone interfaces was assessed.
Measurements of tissue volume and thickness
For each patient, the 1-mm-thick reconstructed images were transferred to a dedicated workstation (Vitrea version 6.1). Both maximum-intensity projection images and three-dimensional (3D) volume rendering (9,10) were used to assess tissue thickness of facial features ( Figure 2 ). Tissue thickness measurements were obtained using the software measurement tool, and volumes were obtained by semiautomated software from the vendor.
Histology
Skin biopsies were performed 0, 6, 18 and 36 months after transplantation. Tissues were fixed in formalin, embedded in paraffin and stained with hematoxylin and eosin (H&E). Epidermal thickness was measured, and changes in skin structure were assessed. Excess muscle tissue was procured from all patients during secondary procedures performed 38-40 months after transplantation. Muscle biopsy specimens were embedded in frozen tissue matrix and cooled by liquid nitrogen. Frozen sections were cut in cross-and longitudinal sections at 6 mm and stained with H&E, Masson's trichrome, periodic acid-Schiff, Oil Red O, NADP, nicotinamide adenine dinucleotide phosphate, and ATPase at acidic pH.
Results

Clinical changes
As seen in the left column of Figure 1 , at 6 months after facial transplantation, the skin appeared clinically normal, with normal turgor and a soft, smooth and even presentation. This appearance is concomitant with patients regaining limited muscle function that enables limited smiling and frowning, signs indicative of the beginning of reinnervation of the transplanted muscle tissue. At 18 months after transplantation (Figure 1 , center column), there was an appreciable decrease in cheek fullness, and irregularities in skin texture were apparent. At this point, muscle function was improved compared with the 6-month time point. After 36 months (Figure 1 , right column), there was a further decrease in turgor and fullness. A dull and uneven skin tone was appreciable. Sagging of the jaw line and pronunciation of the nasolabial fold and the orbital rim were present. Despite these changes, muscle function showed further improvement with respect to the earlier time points.
Total graft volume
The total allograft volume decreased for all three patients ( Figure 2 , Table 2 ). From 6 to 18 months after transplant, the mean of the total graft volume decreased by 6.1%. Between 18 and 36 months, mean allograft volume loss was 11.5% with respect to the original volume. The total allograft volume decreased by a mean of 19.6% between 6 and 36 months after transplantation. These findings are represented in the clinical pictures by a visible loss of facial volume, especially in the cheek regions of the allografts. Patient 1 underwent two secondary procedures involving skin and subcutaneous tissue resection between the 6-and 18-month scans and thus was excluded from the total graft volume analysis over this time frame.
Graft bone volume
The allograft bone volume decreased by 17.2% between 6 and 18 months and by 4.24% of the original volume between 18 and 36 months ( Figure 3 , Table 2 ). In terms of visible changes, bone volume appears to have most strongly affected the clinical outcome of patient 3 because this patient was transplanted with the biggest volume of bone in this cohort. Bone loss may have contributed to Male  25  48  2  Male  Male  30  31  3 Female Female 57 42 Figure 1 ), a loss of fullness of the entire face can be observed. Loss of fullness appears more prominent in the cheeks (white arrows). Furthermore, loss of fullness in the orbital, infraorbital, zygomatic, oral, and mental regions is apparent. Graft nonfat soft tissue volume Nonfat soft tissue decreased by 10.1% between 6 and 18 months, by 15.5% between 18 and 36 months and by 25.6% between 6 and 36 months. This tissue compartment is the highest contributor to the volume of the facial allograft; loss of nonfat soft tissue appears to have particularly affected the buccal, oral, infraorbital, zygomatic and orbital regions ( Figure 1 ).
Graft fat soft tissue volume
Fat tissue did not significantly change within the follow-up period, decreasing by 1.18% between 6-and 18-month scans, by 2.19% between 18 and 36 months, and by 4.73% between 6 and 36 months. Patient 1 underwent two secondary procedures involving skin and subcutaneous tissue resection between the 6-and 18-month scans and thus was excluded from fat volume analysis involving this time frame.
Donor-recipient bone union
Patients 1 and 2 demonstrated complete bony union at 36 months after transplantation. Patient 3, however, showed fused bone on the right side but not on the left.
Graft soft tissue thickness
The soft tissue thickness measurements demonstrated a consistent decrease after transplantation (Figure 4 , Table 2 ), consistent with the volume measurements. Most prominent values were seen at glabella, upper lip and gnathion, with a decrease of >30%. These findings are represented clinically by a noticeable volume reduction in the lower frontal region, the upper lip and the mental region.
Graft tissue biopsies
Muscle biopsy at 36 months included diagnostic muscle fibers and showed atrophic changes ( Figure 5 ). Skin biopsies obtained 0, 6, 18, and 36 months after transplant did not show significant decreases in epidermal thickness and/or collagen or fat content ( Figure 6 ).
The patients' weight did not significantly change over the follow-up period.
Discussion
As a non-life-saving procedure with potential life-threatening side effects, face transplantation presents unique ethical challenges. Consequently, the long-term outcomes of this nascent field should be elucidated to enable accurate assessment of the risk-benefit ratio for candidate selection. This paper provides an initial in-depth analysis to discover and define volumetric and morphometric changes after facial allotransplantation and to propose potential countermeasures.
Postprocessing of CT images to determine tissue volumes has been validated (11) as an accurate tool (12) , including assessment of tissue volume changes after intervention (13) . This study capitalized on this technology to investigate volume loss as one of the major factors in normal facial aging. Normal facial aging is a dynamic process that is attributed mainly to epidermal thinning (14) and atrophy of the deep and superficial fat compartments (15) . Gravity and muscle pull contribute and lead to the appearance of wrinkles and pronunciation of dynamic lines. Changes in the soft tissue integument demonstrate the most dramatic postadolescent changes, whereas the role of skeletal changes is still discussed controversially (16, 17) . Fat atrophy is most apparent in the forehead, periorbital, temporal, perioral, and buccal areas, leading to the loss of youthful convex contours (17) . The accelerated atrophy with volume loss of nonfat soft tissue and bone in facial allografts may resemble changes of skin and fat atrophy seen in normal facial aging. Atrophy of the epidermis, dermis or subcutis typically seen in chronologic aging was not observed in the facial allograft skin biopsies. Although this constitutes the first report of signs of changes resembling accelerated aging of the facial allograft in a cohort of face transplant recipients, these changes-unlike those of physiological aging-seem restricted to bone and soft tissues. This significant and uniform loss of volume in specific compartments of full facial allografts over a 3-year follow-up period was demonstrated with CT data. Histological analysis of donor muscle tissue at 40 months after transplantation confirmed atrophic muscle in the nonfat soft tissue compartment. Importantly, volumetric changes in the allograft did not correlate with patients' changes in weight.
The loss of muscle volume in the facial allografts may be due to muscle atrophy. Initial lack of innervation with impairment of motor function in the nonfat soft tissue compartment of the facial allograft is likely a major causal factor. This is similar to, for example, changes that take place after rotator cuff injuries (18) . Furthermore, all three face transplant recipients in this study experienced acute rejection episodes during the first 36 months. The individual rejection episodes of each patient and their diagnosis and treatment are summarized in Table 3 as well as infectious and surgical events in Table 4 . Multiple acute rejection episodes may have contributed to muscle volume loss, as suggested by a recent report using a rodent hind limb transplantation model (19) . Overall, the experimental data on long-term outcomes of vascularized composite allotransplantation (VCA) procedures are rather sparse. There is currently no animal model for investigating long-term effects of subclinical or chronic rejection; instead, all experimental models in small and large animals rely on severe acute rejection to simulate a long-term outcome (19) (20) (21) . Whether or not this simulation is accurate remains for debate. Experimental animal models enabling the assessment of chronic rejection in the field of solid organ transplantation should be transferred to explore similarities Each patient experienced up to three rejection episodes. All events were resolved with immunosuppressive rescue therapies. Successful treatment was confirmed via biopsy. ATG, anti-thymocyte globulin; MMF, mycophenolate mofetil. and differences in the long-term behavior of VCAs (22, 23) . These models mainly feature non-major histocompatibility mismatch models, which differ only at minor histocompatibility loci. Inflammation and related mediators (e.g. tumor necrosis factor a) present during acute rejection are known to be potent triggers of muscle wasting and cachexia (24) . Although no definition of chronic rejection has been formalized for VCA so far, potential complications listed in context with the Banff classification for skin containing composite tissue allografts include muscle atrophy (25) . All patients were treated with an experimental protocol including thymoglobulin induction, early steroid withdrawal and long-term dual maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF). Tacrolimus and MMF have been shown to protect against occurrence of intimal hyperplasia in larger caliber vessels of solid organ transplants (26, 27) ; however, a similar immunosuppressive regimen with thymoglobulin induction and dual immunosuppression with tacrolimus and MMF after steroid withdrawal demonstrated an increased tendency for the development of interstitial fibrosis in kidney transplantation (28) . These effects should be monitored closely in VCA because it is possible that this could have some relevance to facial allografts.
The loss of bone volume may be partially attributed to side effects of the necessary immunosuppression. Although steroids were withdrawn between 2 and 6 months after transplantation, the literature describes rapid bone loss early after transplantation by exposure to a combination of steroids and calcineurin inhibitors such as tacrolimus (29) . Similarly, our results consistently show higher decreases in bone volume between 6 and 18 months compared with those that took place between 18 and 36 months after transplantation. Bone loss rates after solid organ transplantation are stunningly high during the first 6 months after transplantation, with fracture rates of up to 73% (30) (31) (32) .
It is reported that the bone stabilizes beyond the first year after transplant (33) , and that aligns with our findings.
Complete bony union was shown in two of the three patients; however, patient 3 did not show complete bony union at the left donor-recipient interface. This may explain an asymmetrical bone volume loss of the donor maxilla with more reduction on the left side ( Figure 3) .
The results of this study suggest the need for introduction of effective countermeasures to sustain the aesthetic outcomes of facial allotransplantation. Available techniques to optimize the alignment of donor-recipient bony structure interfaces should be considered, including digital planning (34, 35) and 3D printing (36) .
The transplantation procedure with dissection and coaptation of motor nerves triggers anterograde degeneration within the allograft (37) . Failed timely axonal regeneration leads to muscle atrophy (38) . Consequently, strategies to accelerate nerve regeneration, such as stem cell-based approaches (39) , may be implemented in the future. Temporary musculoskeletal conditioning through short periods of low-intensity, low-frequency electrical impulses have the potential to bridge the time during muscle hypoinnervation (40, 41) .
Currently, we perform immunohistochemical and immunofluorescence assessment of the microvasculature on suspicion of antibody-mediated rejection (42) . Future monitoring strategies also should include closer assessment of the graft's microvasculature and noninvasive routine monitoring of major allograft arteries for evaluation of chronic changes.
A limitation of this study is the small sample size. An increasing number of facial allotransplantations have been performed in recent years, and we hope that more reports regarding the presented topic will become available in the future. Whether the donor age, the recipient age and the age difference between the donor and the recipient affect the resemblance of aging will need to be monitored in the future as more long-term follow-up data become available.
Another limitation of the methods is the subjective correction of the allograft boundaries by the plastic surgeon necessary for the scan assessment.
In conclusion, this study illustrates how facial allografts are subject to substantial transformation in the initial 3 years after transplant. We demonstrate that although these changes imitate aging, they differ from the mechanisms of normal facial aging in that there is neither volume loss in the facial fat compartments nor consistent skin atrophy with loss of epidermal thickness. These findings may have implications for risk-benefit assessment and donor selection for facial allograft transplantation and for potential standard secondary procedures after transplantation. Countermeasures to reverse, delay or even prevent muscle and bone atrophy in facial allotransplants will help improve outcomes in the future. Superior long-term outcomes of facial allotransplantation will be the crucial factor to advance toward clinical routine.
